Why cheap copycat Ozempic is still everywhere

Tech Insider : Economy, Business
Sleazy dealer wearing an open jacket, revealing counterfeit Ozempic pens in his pocket.

Getty Images; Alyssa Powell/BI

The copycat weight-loss drugs party was supposed to be over, but it's still raging on.

Here's what Big Pharma could buy in 2025, from obesity drugs to precision cancer treatments, according to a top M&A banker

Tech Insider : Business
Red pills with $100 bills wrapped around them.
Chris Roop, head of M&A for the Americas at investment bank Jefferies, said Big Pharma will be looking for new drugs to boost growth in 2025.

GP Kidd/Getty Images

5 new weight-loss drugs to watch in the fight for the next Ozempic

Tech Insider
A pill
The race is on to make a weight-loss pill that is as effective as injectables like Ozempic, Wegovy, Mounjaro, and Zepbound.

Getty Images

Weight-loss drugs are life-changing — and expensive. Here's one woman's solution.

Tech Insider
Portrait image of Tara Rothenhoefer
Tara Rothenhoefer has been taking tirzepatide for more than four years, and only in the past six months has she felt secure in having an affordable supply.

Octavio Jones for BI

Eli Lilly just halved the price of its weight-loss drug — declaring war on the booming market of knock-offs

Tech Insider
A close up of a person injecting a medication into their stomach
Popular weight loss medication tirzepatide, sold as Zepbound, will now be available at a steep discount from manufacturer Eli Lilly, in an attempt to fight back against cheap knock-off versions of the drug.

Tassii/Getty Images

Eli Lilly's weight-loss drug may prevent diabetes — but there's 1 unanswered question

Tech Insider
mounjaro tirzepatide pen

Sandy Huffaker for The Washington Post via Getty Images

Google's new CFO Anat Ashkenazi raked in a nearly $10 million signing bonus

Tech Insider
Google campus located in California
Google's parent company, Alphabet, on Wednesday announced the appointment of its new CFO, former Eli Lilly executive Anat Ashkenazi.

Melina Mara/The Washington Post via Getty Images

Eli Lilly's Wegovy rival Zepbound will help make weight-loss drug market worth $130 billion by 2030, Goldman Sachs says

Tech Insider
Zepbound
Zepbound is Eli Lilly's new weight-loss drug.

Brendan McDermid/Reuters

A Gen Z diabetic said a 3-month supply of insulin pumps would cost her $1,800 — even with insurance

Tech Insider : Economy, Economy
Grace stands in her scrubs with a stethoscope around her shoulders.
Grace Cochran, 25, is a nurse in Charlotte, North Carolina. On her TikTok account, she share her experience navigating the healthcare system as a Type 1 diabetic.

Grace Cochran

Healthcare companies are promising to help patients quit Wegovy. There's just one problem with that.

Tech Insider
Illustration of person and Ozempic pen.

Cornelia Li for Business Insider

Subscribe to eli-lilly